Long-term safety and immunogenicity of the M72/AS01(E) candidate tuberculosis vaccine in HIV-positive and -negative Indian adults: Results from a phase II randomized controlled trial

OBJECTIVES: To assess the long-term safety and immunogenicity of the M72/ Adjuvant System (AS01(E)) candidate tuberculosis (TB) vaccine up to 3 years post-dose 2 (Y3) in human immunodeficiency virus (HIV)-positive (HIV+) and HIV-negative (HIV−) Indian adults. METHODS: This phase II, double-blind, ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumarasamy, Nagalingeswaran, Poongulali, Selvamuthu, Beulah, Faith Esther, Akite, Elaine Jacqueline, Ayuk, Leo Njock, Bollaerts, Anne, Demoitié, Marie-Ange, Jongert, Erik, Ofori-Anyinam, Opokua, Van Der Meeren, Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6250513/
https://www.ncbi.nlm.nih.gov/pubmed/30407329
http://dx.doi.org/10.1097/MD.0000000000013120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6250513/
https://www.ncbi.nlm.nih.gov/pubmed/30407329
http://dx.doi.org/10.1097/MD.0000000000013120

Ejemplares similares